Analyst Reco. AnaptysBio, Inc.

Equities

ANAB

US0327241065

Real-time Estimate Cboe BZX Other stock markets 14:37:31 29/04/2024 BST			5-day change	1st Jan Change
21.46 ^USD	+2.21%		+5.69%	-1.96%

04-16	Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	MT
04-11	Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	04-16	MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	04-11	MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating	04-01	MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20	03-12	MT
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target	02-26	MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	02-16	MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target	02-16	MT
Wedbush Lifts AnaptysBio's PT to $20 From $18 Due to Updated Cash Guidance, Keeps Neutral Rating	11-03	MT
UBS Cuts AnaptysBio Price Target to $21 From $28, Maintains Neutral Rating	11-01	MT
Wedbush Lowers AnaptysBio's PT to $18 From $26, Adjusts Launch Estimates, Addition of Ulcerative Colitis for Rosnilimab; Keeps Neutral Rating	26/10/23	MT
Wedbush Lowers AnaptysBio's Price Target to $26 From $29, Keeps Neutral Rating	08/08/23	MT
JPMorgan Upgrades AnaptysBio to Neutral From Underweight, Trims Price Target to $30 From $31	22/05/23	MT
Guggenheim Adjusts AnaptysBio Price Target to $45 From $44, Maintains Buy Rating	12/05/23	MT
JPMorgan Adjusts Price Target on AnaptysBio to $31 From $32, Keeps Underweight Rating	12/04/23	MT
Raymond James Downgrades AnaptysBio to Market Perform From Outperform	06/01/23	MT
Wedbush Lowers AnaptysBio's PT to $29 From $32, Removes Valuations for Rosnilimab in Rheumatoid Arthritis, ANB032 in Atopic Dermatitis; Keeps Neutral Rating	06/01/23	MT
JPMorgan Adjusts Price Target on AnaptysBio to $32 From $24, Maintains Underweight Rating	18/11/22	MT
Raymond James Raises Price Target on AnaptysBio to $38 From $30, Maintains Outperform Rating	09/11/22	MT
Wedbush Raises AnaptysBio's PT to $32 From $21, Changes Launch Estimate for Rosnilimab in Alopecia, Adjusts Cost of Capital; Keeps Neutral Rating	09/11/22	MT
Guggenheim Upgrades AnaptysBio to Buy Rating From Neutral	01/11/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AnaptysBio, Inc.

Equities

ANAB

US0327241065

Analyst Reco.

Filters